Literature DB >> 1569294

Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.

A E Pontiroli1, R Lanzi, M Monzani, L Musatti, C Guglielmone, G Pozza.   

Abstract

In normal men, plasma free fatty acids (FFA) are influenced by feeding and by fasting; in addition, iv infusions of methionyl growth hormone (met-GH), so far performed during morning hours, induce an FFA rise that can be blocked by acipimox (ACX), a nicotinic acid analogue. The aims of the present study were to evaluate, in the absence of food interferences, the following aspects: i) Fasting FFA, glycerol, and insulin (IRI) in the morning and in the evening, and their response to met-GH ii) The effect of ACX and of a sustained release ACX formulation (ACX-SR) on fasting and met-GH induced lipolysis and on IRI levels. In a double blind study, 6 normal men received 50% cal at 09:30 h and 50% at 21:30 h; during placebo administrations FFA, glycerol, and IRI levels were lower at 06:30 h than at 18:30 h, and an iv met-GH infusion (160 ng/kg/min lasting 180 min) had a similar effect on FFA and on glycerol at 06:30 h and at 18:30 h. ACX-SR, administered at 21:30 h and 09:30 h, lowered FFA and glycerol in the morning as well as in the evening, and prevented met-GH induced lipolysis in the morning, but not in the evening.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569294     DOI: 10.1007/BF03348669

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles.

Authors:  P J Randle; E A Newsholme; P B Garland
Journal:  Biochem J       Date:  1964-12       Impact factor: 3.857

2.  Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects.

Authors:  M B Turton; T Deegan
Journal:  Clin Chim Acta       Date:  1974-09-30       Impact factor: 3.786

3.  Diurnal variation in insulin sensitivity.

Authors:  T Gibson; R J Jarrett
Journal:  Lancet       Date:  1972-11-04       Impact factor: 79.321

4.  Inhibition of the growth hormone (GH) response to GH-releasing hormone by constant Met-GH infusions.

Authors:  A E Pontiroli; R Lanzi; G Pozza
Journal:  J Clin Endocrinol Metab       Date:  1989-05       Impact factor: 5.958

5.  Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone, and glucagon concentrations.

Authors:  A Golay; A L Swislocki; Y D Chen; J B Jaspan; G M Reaven
Journal:  J Clin Endocrinol Metab       Date:  1986-08       Impact factor: 5.958

6.  Circadian rhythm of catecholamines, cortisol and prolactin is altered in patients with apallic syndrome in comparison with normal volunteers.

Authors:  D Ratge; E Knoll; U Diener; A Hadjidimos; H Wisser
Journal:  Acta Endocrinol (Copenh)       Date:  1982-11

7.  Effect of fatty acids on glucose production and utilization in man.

Authors:  E Ferrannini; E J Barrett; S Bevilacqua; R A DeFronzo
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

8.  Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals.

Authors:  A Golay; A L Swislocki; Y D Chen; G M Reaven
Journal:  Metabolism       Date:  1987-07       Impact factor: 8.694

9.  Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.

Authors:  L Musatti; E Maggi; E Moro; G Valzelli; V Tamassia
Journal:  J Int Med Res       Date:  1981       Impact factor: 1.671

10.  Short-term met-hGH infusion inhibits somatotroph response to growth hormone releasing hormone (1-44).

Authors:  M Rosenbaum; S Loche; S Balzano; J M Gertner
Journal:  Metabolism       Date:  1988-02       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.